Case report

Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease

Antonio Riccardo Buonomo, Giulio Viceconte, Debora Compare, Maria Vargas, Carmine Iacovazzo, Emanuela Zappulo, Gerardo Nardone, Giuseppe Servillo, Guglielmo Borgia, Ivan Gentile

*Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Italy
bDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, via Pansini, Naples, Italy
cDepartment of Clinical Medicine and Surgery, Section of Gastroenterology, University Federico II of Naples, Naples, Italy

ABSTRACT

We report a case of concurrent development of active pulmonary tuberculosis and invasive pulmonary aspergillosis (IPA) in a patient who received therapy with infliximab for Crohn’s disease. He has been treated with antitubercular therapy and liposomal amphotericin B for 8 weeks. His clinical course was complicated by paroxysmal atrial fibrillation requiring maintenance therapy with amiodarone, respiratory failure due both to pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamases (ESBL)-producing Klebsiella pneumoniae and pleural effusion requiring chest drainage. At discharge, a maintenance regimen based on the administration of isavuconazole 200 mg daily, moxifloxacin 400 mg daily and isoniazid 300 mg daily was chosen to avoid multiple drug-drug interaction between rifamycins, antifungal triazole agents and antirrhhythmic drugs. At 3 months of follow-up his clinical conditions were dramatically improved, high resolution chest tomography (HRCT) showed reduction of parenchymal lesions and no changes both in sinus rhythm and QTc interval were noticed. Besides the complexity and the peculiarity of the clinical scenario, this case underlines the risk of invasive fungal infections linked to the administration of TNF-α antagonists in gastroenterological setting and the importance of accurate evaluation of drug-drug interactions when choosing the antimicrobial therapies.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Tuberculosis is a known infective complication that may occur after the administration of TNF-α antagonists. Accumulating evidence suggests that biologic drugs for autoimmune diseases also play a role in the development of other opportunistic infections such as aspergillosis [1–7]. The concurrent development of both active tuberculosis and acute invasive aspergillosis in a single patient who underwent infliximab therapy has been only described once [3] and it raises questions about the pharmacological interactions between antitubercular, antifungal drugs and other therapies for concomitant diseases.

Case report

A 48-year-old Northern African man affected by Crohn's disease, protein-energy malnutrition and lymphopenia presented with fever, cough and respiratory failure in March 2018. He had received therapy with infliximab in December 2017. He received the last dose one month before the development of symptoms. His baseline Mantoux test was negative. At admission, a high resolution computed tomography (HRCT) showed bilateral pleural effusion, large parenchymal consolidation on the upper lobe, bilateral nodular consolidations, multiple mediastinic lymphadenopathies. We performed bronchoalveolar lavage (BAL) that showed positivity for M. tuberculosis PCR (Xpert MTB/RIF®), Quantiferon®-TB Gold Plus test resulted indeterminate. We than started antitubercular therapy with rifampicin 600 mg, isoniazid 300 mg, ethambutol 1200 mg and pyrazinamide 1500 mg plus pyridoxine 300 mg 3 times per week. He was also on treatment with dexamethasone 8 mg twice daily and on total parenteral nutrition due to the poor clinical condition.

https://doi.org/10.1016/j.idcr.2019.e00537
2214-2509/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
At admission he had WBC 2,300/µL, lymphocytes 440/µL, CD4+ 250/µL, hemoglobin 9.9 g/dL, C-reactive protein (CRP) 2.68 mg/dL (upper normal value 0.5). He reported penicillin allergy. The ECG on admission showed sinus rhythm with a QTc interval of 390 ms. Three days later, he developed atrial fibrillation that was successfully cardioverted with amiodarone. He remained apyretic for the following 7 days and the steroid dosage was slowly tapered to 4 mg of dexamethasone per day. Over the next two days he developed fever with chills and progressive worsening of dyspnea. All the blood cultures resulted negative.

Five days later, he developed respiratory failure, and another HRCT showed worsening of the pleural effusion and of the parenchymal lesions, with the appearance of new areas of consolidation. CRP was 12.7 mg/dL. Empiric therapy with linezolid and meropenem was added. In addition, we performed a second bronchoscopy and a thoracentry. The Gene Xpert MTB/RIF test resulted negative both on BAL fluid (BALF) and on pleural fluid. BALF culture resulted positive for extended-spectrum beta-lactamase producer (ESBL) Klebsiella pneumonia and methicillin-resistant Staphylococcus aureus (MRSA). Moreover, galactomannan determination on BALF resulted strongly positive and, therefore, liposomal amphotericin B (L-AmB) therapy was started at 3 mg/kg/day.

Despite a slight improvement during the first days of antimicrobial therapy, ten days after the BAL he developed again respiratory failure (PaO2/FiO2 ratio: 129). We performed another HRCT that showed worsening of the bilateral pleural effusion that required left chest drainage tube placement. Oxygen therapy and dexamethasone (8 mg L.V. BID) were reintroduced. After that, he became apyretic and CRP levels declined (from 13.9 mg/dL to 1.4 mg/dL during the next ten days). Antibiotics were interrupted after 21 days. In the meantime, steroidial therapy was progressively tapered. He stopped ethambutol and pyrazinamide after 8 weeks of treatment and he continued with TB maintenance therapy; chest drainage tube was removed after 27 days. During L-AmB therapy hypokalemia occurred, with daily need for potassium supplementation.

After 8 weeks of antifungal therapy, L-AmB was interrupted, rifampin was substituted with moxifloxacin 400 mg per day and isavuconazole was started at 200 mg every 8 h for the first 48 h, followed by 200 mg daily, along with daily ECG monitoring. No significant alterations in sinus rhythm and QTc interval were seen during therapy with isavuconazole compared to baseline ECG on admission. After the withdrawal of L-AmB, potassium levels returned normal. He was discharged after 83 days of hospitalization in good clinical conditions on maintenance therapy with isavuconazole 200 mg daily, moxifloxacin 400 mg daily and isoniazid 300 mg daily.

After discharge, no alteration in sinus rhythm and QTc interval was noticed at weekly follow-up. On follow-up chest HRCTs performed one and three months later, pulmonary lesions and pleural effusion were significantly reduced.

He received a total of 24 weeks of antitubercular and antifungal therapy.

Discussion

The use of biologic drugs for treating autoimmune diseases, including TNF-α antagonists, is associated with an increased risk of opportunistic infections [1,6,8]. Risk of invasive aspergillosis in patients treated with TNF-α antagonists is assumed to be low compared with TB and it is higher in patients with neutropenia [1]. However, only 35 cases of aspergillosis following TNF-α antagonist therapies are reported [1–57].

The concurrent development of tuberculosis and invasive aspergillosis has been rarely described, mostly in onco-hematologic settings [3,9]. We report the second case of such co-infection after TNF-α antagonists-based therapy [3]. Moreover, the described case raises important issues about the management of pharmacologic interactions between the prescribed drugs.

Although voriconazole is a first line drug for the treatment of invasive aspergillosis [10], its use is limited by multiple potential drug-drug interactions, as it is both substrate and inhibitor of CYP3A4, CYP2C9, CYP2B6 and CYP2C19 cytochromes [11]. Thus, we started aspergillosis treatment with L-AmB, since the coadministration of rifampin or rifabutin could have significantly reduced the voriconazole serum concentration by inducing CYP3A4 cytochrome, while the administration of isoniazid might have increased voriconazole concentration by inhibiting CYP2C19 cytochrome [12]. In addition, we pursued this therapeutic choice to avoid the interaction between voriconazole and amiodarone, which might have prolonged QTc interval [13].

Once the patient had to be discharged, we interrupted L-AmB therapy and we prescribed oral isavuconazole as maintenance therapy. Isavuconazole is a recommended alternative primary therapy for IPA which demonstrated non-inferiority to voriconazole, with lower rates of drug-related hepatobiliary, ocular, and skin disorders [10]. It is the only triazole agent that shortens the QTc interval, with no evidence of associated increased cardiac risk [14]. Isavuconazole has fewer drug-drug interactions than other triazoles, but it is metabolized by the CYP3A4/5 pathway. Coadministration with rifampicins is contraindicated because of reduction in isavuconazole plasma concentration [15].

In this case, isavuconazole was chosen as maintenance therapy for IPA because of the favorable interaction profile with amiodarone; interaction with rifampin was prevented by substituting it with moxifloxacin 400 mg once daily. We assumed that the effect of isavuconazole in shortening QTc might have balanced the effect of moxifloxacin in prolonging it.

In conclusion, management of opportunistic infections in patients receiving biological therapies requires a multidisciplinary approach, and the possibility of concomitant infections should always be considered. Moreover, the best therapeutic approach should be evaluated case by case, taking into account the drug-to-drug interactions.

Funding

None.

Ethical approval

None required.

Conflict of interest

None, for all authors.

Informed consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Authors statement

All persons who meet authorship criteria are listed as authors, and all authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript. Furthermore, each author certifies that this material or similar material has not been and will not be submitted to or published in any other publication.
Authors contributions

Conception and design of study: Buonomo Antonio Riccardo, Viceconte Giulio, Compare Debra, Nardone Gerardo, Servillo Giuseppe, Borgia Guglielmo, Gentile Ivan.

Acquisition of data: Buonomo Antonio Riccardo, Viceconte Giulio, Compare Debra, Zappulo Emanuela

Analysis and/or interpretation of data: Vargas Maria, Iacovazzo Carmine, Zappulo Emanuela.

Drafting the manuscript: Buonomo Antonio Riccardo, Viceconte Giulio

Revising the manuscript critically for important intellectual content: Compare Debra, Zappulo Emanuela, Nardone Gerardo, Servillo Giuseppe, Borgia Guglielmo, Gentile Ivan.

All the authors have approved the final version of the manuscript to be published

References

[1] Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Sciré C, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clin Exp Rheumatol [Internet] 2017;35(6):1018–28. [cited 2018 Oct 20] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29185961.

[2] De Rosa FG, Shaz D, Campagna AC, Dellaripa PF, Khettry U, Craven DE, et al. Aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol [Internet] 2003;24(July (07))477–82. [cited 2018 Jul 31]Available from: https://www.cambridge.org/core/product/identifier/S019594170001558/type/journal_article.

[3] van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Speel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med [Internet] 2003;29(December (12)):2327–9 [cited 2018 Jul 31]Available from: http://link.springer.com/10.1007/s00134-003-1867-z.

[4] Alderson JW, Van Dinter TG, Opatomsky MJ, Burton EC, Burton EC. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic hepatitis C: a case study and review of the literature. MedGenMed [Internet] 2005;7:September [3] [cited 2018 Jul 31]Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC16369233.

[5] Bourne E-L, Dimou J. Invasive central nervous system aspergillosis in a patient with Crohn’s disease after treatment with infliximab and corticosteroids. J Clin Neurosci [Internet] 2016;30(August):163–4. [cited 2018 Jul 31]Available from: https://www.sciencedirect.com/science/article/pii/S0967586816000957/via%3Dihub.

[6] Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018;17(July (07)):709–17.

[7] Şeyhohğu E, Erden A, Kılıc L, Karadag O, Akdağlı SA, Akdoğan A, et al. Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis. Eur J Rheumatol [Internet] 2018;5(March (1)):75–8. [cited 2018 Jul 31]Available from: http://www.ncbi.nlm.nih.gov/pubmed/29857880.

[8] Buonomo AR, Saccà F, Zappulo E, De Zotti F, Lanzillo R, Gentile I; et al. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. Mult Scler Relat Disord [Internet] 2019;27(January). [cited 2018 Oct 21]Available from: https://www.sciencedirect.com/science/article/pii/S2210348183035727/via%3Dihub.

[9] Xu Y, Zhao Y, Liu Y, Qian L, Yao W, Tang X, et al. Case report a rare case of synchronous mycobacterium tuberculosis, aspergillosis and lung adenocarcinoma in a patient [Internet]. Int J Clin Exp Pathol 2016;9. Available from: www.ijcep.com/.

[10] Patterson TF, Granger GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016.

[11] Food and Drug Administration. VFEND: (voriconazole). Highlights of prescribing informations [Internet]. [cited 2018 Oct 21]. Available from: p. 1–42. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021266s038,021267s047,021630s028lbl.pdf.

[12] Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by nisozamide: potent inhibition of CYP2C9 and CYP3A. Antimicrob Agents Chemother [Internet] 2001;45(February (2)):382–92. [cited 2018 Sep 23]Available from: http://www.ncbi.nlm.nih.gov/pubmed/11158730.

[13] Cueta I, Loebstein R, Markovits N, Kamari Y, Halkin H, Livni G, et al. Voriconazole-induced QT prolongation among hematopoietic patients: clinical characteristics and risk factors. Eur J Clin Pharmacol [Internet] 2017;73 (September (9))1181–5. [cited 2018 Sep 23]Available from: http://link.springer.com/10.1007/s00228-017-2284-5.

[14] Keirns J, Desai A, Kowalski D, Lademacher C, Mujais S, Parker B, et al. QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization. Clin Pharmacol Ther [Internet] 2017;101(June (6)):782–90. [cited 2018 Sep 23]Available from: http://www.ncbi.nlm.nih.gov/pubmed/28074556.

[15] Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev [Internet] 2017;6 (January (1)):44–53. [cited 2018 Sep 23]Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5277461/.